Therapeutic Response

MSI-H status confers therapeutic sensitivity to Dostarlimab in patients with Endometrial Carcinoma.

Statements

Source and description
Jemperli (dostarlimab) [product information]. EMA. The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.